Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma. - Wikidata - wikimedia - TriplyDB

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

http://www.wikidata.org/entity/Q33557934

about

EQ-5D Health Utility Scores: Data from a Comprehensive Canadian Cancer Centre.Testing mapping algorithms of the cancer-specific EORTC QLQ-C30 onto EQ-5D in malignant mesothelioma Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L.Cost-Effectiveness of Autologous Stem Cell Treatment as Compared to Conventional Chemotherapy for Treatment of Multiple Myeloma in India.Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and/or refractory multiple myeloma.Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia.Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.The Development of Quality of Life Questionnaire for Indonesian Breast Cancer Patients: INA-BCHRQoL

P2860

Q31124402-498648FF-6339-4D6E-8A8D-FD0A7AC597E2 Q35047438-880E6B08-408E-4C16-A410-09357DFAF008 Q36070909-972E0829-D67C-4A49-99F1-2B9717FB5674 Q38757989-0BE808BD-9119-4348-9E0A-BC3F3AFF7E22 Q39346865-36191900-CEFA-4E7C-A360-44EDF594E285 Q39737036-B5348307-86D8-4423-9679-2C3FBE972243 Q42940568-CF63BA27-E9E8-4AE1-AD50-6894E99ED8EA Q47673299-00D104E6-3B4F-484D-8B2B-06E15F175D30 Q47804400-656BC20C-8496-446A-B48D-754858A02054 Q47960020-256B33A0-0410-44DF-A9D9-FCBC8D337403 Q48060040-6FCF4484-E3D0-4049-88AA-3CCA92435EB1 Q55709549-C97FACDD-C72B-4CEF-B9CE-6871FA36EE54

P2860

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

http://www.wikidata.org/entity/Q33557934

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@ast

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@en

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@nl

type

label

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@ast

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@en

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@nl

prefLabel

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@ast

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@en

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@nl

P1433

Q33557934-68570C62-71BA-41BF-9CC1-02B973E744BD

P1476

Q33557934-EF0030B5-9271-4C2D-A991-16EC9F95DDE0

P2093

Q33557934-04DD9BDE-B6FE-47A2-AB07-8DABE5FC1A43

Q33557934-4E3FB84C-8EAC-4144-AD65-A0F8E5F7B082

Q33557934-802622BB-A734-4952-9E1A-8E55054A4497

Q33557934-8457B657-07A1-493D-98E3-40642C9221A6

Q33557934-8DAB973C-0FEF-4F29-90C1-3F2F2B3D5293

Q33557934-CEB4AADE-7C4C-4F74-9BB7-2E0377821BC8

Q33557934-DAE8D261-BD0C-4895-9E33-D2C58DBF56F1

P2860

Q33557934-0E67EA4B-0BB0-4923-9C32-6043D6620F78

Q33557934-19482B10-1141-41E0-BF48-7215F9CF4214

Q33557934-48FFCF54-3AF5-4881-9F81-5C938BCD3A43

Q33557934-4F4AE181-29EB-440B-AC04-73B7D37AEEE2

Q33557934-5F460922-3689-4D5C-82D1-588588F3E218

Q33557934-6A499273-6621-427D-A77C-9D0B8046F74D

Q33557934-805D4ABC-6B7F-4882-81B5-AF4E1BBEBF58

Q33557934-88FAECA7-8088-4C2C-AFDA-538DFBCA87BC

Q33557934-9753E770-C0C5-4558-98D7-17FBD3D9B162

Q33557934-983DBCFB-75C6-4B8C-9473-F5DE154A5A27

P2888

Q33557934-5FDC8EE1-5188-4564-ABDD-E5121B082BC9

P304

Q33557934-86C5B499-871A-4BEF-9BE9-D5FB96C46D2F

P31

Q33557934-CB26E498-D3A3-44E4-9C25-F25C7CDA5F04

P356

Q33557934-370764BE-FB3C-458D-9A64-1A995176FDDB

P478

Q33557934-D44ACD2F-E7D7-4932-9B64-D3738541F5FB

P577

Q33557934-B497E2A6-B5E1-4804-AE0A-75BCB62682CD

P5875

Q33557934-D6455CE8-BE2D-414B-AE45-5D298D5F3F9F

P6179

Q33557934-E504AA6D-8CC2-4EED-BB31-CC4BC73CE59F

P698

Q33557934-C064A795-9DC2-4074-8F8A-6E73FC1D250D

P932

Q33557934-5C0B9C2D-D7CD-4411-AB4C-72228ACD5894

P356

1477-7525-12-35

P1433

Health and Quality of Life Outcomes

P1476

Mapping EORTC QLQ-C30 and QLQ-MY20 to EQ-5D in patients with multiple myeloma.

@en

P2093

Cathy D Williams

http://www.w3.org/2001/XMLSchema#string

Charalampia Kyriakou

http://www.w3.org/2001/XMLSchema#string

Faith E Davies

http://www.w3.org/2001/XMLSchema#string

Irina Proskorovsky

http://www.w3.org/2001/XMLSchema#string

Jack Ishak

http://www.w3.org/2001/XMLSchema#string

Karin Jordan

http://www.w3.org/2001/XMLSchema#string

Philip Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: the potential to estimate QALYs without generic preference data.

Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged ≥ 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial.

The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities.

Deriving a preference-based measure for cancer using the EORTC QLQ-C30

Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study

Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals.

Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome).

Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial.

Generic and disease-specific measures in assessing health status and quality of life.

P2888

1477-7525-12-35

P304

35

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1477-7525-12-35

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P577

2014-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260717326

http://www.w3.org/2001/XMLSchema#string

P6179

1048346827

http://www.w3.org/2001/XMLSchema#string

P698

24618388

http://www.w3.org/2001/XMLSchema#string

P932

4007827

http://www.w3.org/2001/XMLSchema#string